Commercial Daiichi Sankyo shares slip after delaying annual earnings report BioSpaceDaiichi Sankyo's full-year report was originally scheduled for April 27 but has now been pushed back to May 11.CommercialRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) BioSpace Daiichi Sankyo’s full-year report was originally scheduled for April 27 but has now been pushed back to May 11. CommercialRead full story Post navigation Previous: Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancerNext: Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026